Israel
· Delayed Price · Currency is ILS · Price in ILAPurple Biotech Statistics
Total Valuation
Purple Biotech has a market cap or net worth of ILS 43.09 million. The enterprise value is 16.48 million.
| Market Cap | 43.09M |
| Enterprise Value | 16.48M |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Purple Biotech has 321.60 million shares outstanding. The number of shares has increased by 30.82% in one year.
| Shares Outstanding | 321.60M |
| Shares Change (YoY) | +30.82% |
| Shares Change (QoQ) | +1.54% |
| Owned by Insiders (%) | 0.74% |
| Owned by Institutions (%) | 1.76% |
| Float | 279.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.33 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.27 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.25 |
Financial Position
The company has a current ratio of 1.22, with a Debt / Equity ratio of 0.89.
| Current Ratio | 1.22 |
| Quick Ratio | 1.14 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -44.67% and return on invested capital (ROIC) is -33.77%.
| Return on Equity (ROE) | -44.67% |
| Return on Assets (ROA) | -29.25% |
| Return on Capital (ROIC) | -33.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -3.02M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.09% in the last 52 weeks. The beta is 0.41, so Purple Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | -70.09% |
| 50-Day Moving Average | 15.19 |
| 200-Day Moving Average | 23.99 |
| Relative Strength Index (RSI) | 37.05 |
| Average Volume (20 Days) | 270,969 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -737,960 |
| Operating Income | -74.05M |
| Pretax Income | -60.66M |
| Net Income | -60.36M |
| EBITDA | -73.89M |
| EBIT | -74.05M |
| Earnings Per Share (EPS) | -0.24 |
Balance Sheet
The company has 27.83 million in cash and 982,691 in debt, giving a net cash position of 26.85 million or 0.08 per share.
| Cash & Cash Equivalents | 27.83M |
| Total Debt | 982,691 |
| Net Cash | 26.85M |
| Net Cash Per Share | 0.08 |
| Equity (Book Value) | 110.61M |
| Book Value Per Share | 0.40 |
| Working Capital | 5.26M |
Cash Flow
In the last 12 months, operating cash flow was -66.63 million and capital expenditures 3,765, giving a free cash flow of -66.62 million.
| Operating Cash Flow | -66.63M |
| Capital Expenditures | 3,765 |
| Free Cash Flow | -66.62M |
| FCF Per Share | -0.21 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Purple Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.82% |
| Shareholder Yield | -30.82% |
| Earnings Yield | -177.99% |
| FCF Yield | -154.60% |
Stock Splits
The last stock split was on January 6, 2019. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jan 6, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.05 |